Strategic Family Wealth Counselors L.L.C. Purchases 1,410 Shares of Eli Lilly and Company $LLY

Key Points

• Strategic Family Wealth Counselors L.L.C. boosted its Eli Lilly position by 524.2% in the fourth quarter, ending with 1,679 shares worth about $1.748 million.
• Wall Street sentiment remains constructive: several analysts raised price targets, and the stock now carries a “Moderate Buy” consensus with an average target of $1,218.33.
• Recent business updates were mostly positive, including strong phase 3 obesity data, progress on next-generation weight-loss drugs, and solid quarterly results with EPS of $8.55 and revenue of $19.8 billion beating estimates.

Strategic Family Wealth Counselors L.L.C. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 524.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,679 shares of the company's stock after buying an additional 1,410 shares during the quarter. Strategic Family Wealth Counselors L.L.C.'s holdings in Eli Lilly and Company were worth $1,748,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of LLY. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP grew its holdings in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares in the last quarter. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $33,000. Finally, Hopwood Financial Services Inc. grew its holdings in shares of Eli Lilly and Company by 113.6% during the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company's stock worth $36,000 after buying an additional 25 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on LLY shares. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, May 4th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research note on Wednesday, February 11th. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a "buy" rating in a research note on Friday, May 1st. Finally, Morgan Stanley restated an "overweight" rating and issued a $1,344.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,218.33.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s new phase 3 obesity data suggest Foundayo and lower-dose Zepbound can preserve weight-loss results, strengthening confidence in its obesity franchise and future growth. Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
• Positive Sentiment: Coverage highlighting Lilly’s strategy to expand beyond tirzepatide with next-generation obesity drugs, including an oral pill and retatrutide, may reassure investors that the company is protecting its leadership position. Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
• Positive Sentiment: Additional long-term data for Omvoh in ulcerative colitis adds another proof point for Lilly’s non-obesity pipeline and supports the broader growth story. Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
• Neutral Sentiment: Lilly is celebrating its 150th anniversary with various company, community, and leadership-profile stories, but these are mostly reputational and unlikely to move the stock much on their own. Lilly CEO David Ricks keeps eye on future while company celebrates history
• Neutral Sentiment: Reuters reported Lilly launched its Alzheimer’s drug in India, a positive commercial development, but the immediate financial impact may be limited given the market’s focus on obesity growth. Eli Lilly launches Alzheimer's drug Donanemab in India
• Negative Sentiment: Rival GLP-1 developers and new obesity entrants, including Kailera Therapeutics, add competitive pressure and show that Lilly’s market will remain highly contested. This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
• Negative Sentiment: Reports that Lilly paused an obesity awareness campaign in India after regulatory notices could be a modest headwind, though it does not appear to be a major earnings issue. Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,014.93 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The stock has a 50 day moving average of $939.87 and a 200-day moving average of $995.67. The company has a market capitalization of $955.80 billion, a P/E ratio of 36.05, a P/E/G ratio of 1.08 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the company posted $3.34 EPS. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.